Prevalence of Huntington Disease in Italy: a systematic review and meta-analysis

Main Article Content

Matteo Riccò http://orcid.org/0000-0002-6525-2159
Luigi Vezzosi http://orcid.org/0000-0001-6461-2231
Federica Balzarini https://orcid.org/0000-0002-2104-8471
Giovanni Gualerzi
Silvia Ranzieri http://orcid.org/0000-0002-9607-8624

Keywords

Huntington’s disease, Prevalence, Neurodegenerative disorders, Analyses, genetic linkage, Italy

Abstract

Worldwide prevalence of Huntington’s disease (HD) is quite heterogenous. As Italy is characterized by significant genetic heterogeneity, with presumptive differences between Italian regions, this review was undertaken to define available data of HD prevalence in Italy, to assess geographic heterogeneity, and reconcile possible variation in HD prevalence rates with the availability of genetic testing. Methods. In total, 14 relevant studies were identified from Medline/Embase, and analysis of available Italian regional reports on rare diseases. Results. A cumulative prevalence of 3.9/100,000 inhabitants (95% Confidence Interval 3.0 – 5.0) was identified, with apparently higher rates in the last decades (4.1/100,000 vs. 3.0/100,000). The lowest rates were among the resident of the Oristano province in Sardinia, while the highest were reported in three mountainous and rather isolated areas (i.e. Molise, San Marino, Varese; all well over 10 cases/100,000 inhabitants). These differences cannot be not fully explained by varying approaches to case-ascertainment or diagnosis, and a possible “founder effect” may therefore be extensively advocated. Discussion. The prevalence of HD in retrieved Italian reports varied up to almost tenfold between different geographical regions. Even though such variation can in part be attributed to differences in case-ascertainment and/or diagnostic criteria, there is consistent evidence of significant founder effects in certain areas such as the provinces of Varese, the Republic of San Marino, and the region od Molise – all of them with estimates > 10/100,000 cases. As our estimates suggest that up to half of Italian HD cases may be still waiting, Public Health approach should improve diagnostic rates in order to guaranteeing palliative and symptomatic interventions (antidepressants, antipsychotics, anti-choreiform medications) to all individuals and their families.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 197 | PDF Downloads 97

References

1. Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Mov Disord. 2012;27(9):1083–91. doi: 10.1002/mds.25075
2. Walker FO. Huntington’s disease. Lancet. 2007;369(9557):218–28. doi: 10.1016/S0140-6736(07)60111-1
3. Ross CA, Tabrizi SJ. Huntington’s disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98. doi:10.1016/S1474-4422(10)70245-3
4. Chao TK, Hu J, Pringsheim T. Risk factors for the onset and progression of Huntington disease. Neurotoxicology [Internet]. 2017;61:79–99. doi: 10.1016/j.neuro.2017.01.005
5. Ha AD, Fung VSC. Huntington’s disease. Curr Opin Neurol. 2012;25(4):491–8. doi: 10.1097/WCO.0b013e3283550c97
6. Long JD, Mills JA, Leavitt BR, Durr A, Roos RA, Stout JC, et al. Survival end points for Huntington disease trials prior to a motor diagnosis. JAMA Neurol. 2017:74(11):1352–60. doi: 10.1001/jamaneurol.2017.2107
7. Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW, et al. The Prevalence of Huntington’s Disease. Neuroepidemiology. 2016;46(2):144–53. doi: 10.1159/000443738
8. Carrassi E, Pugliatti M, Govoni V, M. S, Casetta I, Granieri E. Epidemiological Study of Huntington’s Disease in the Province of Ferrara, Italy. Neuroepidemiology]. 2017;49(1–2):18–23. doi: 10.1159/000479697
9. Baig SS, Strong M, Quarrell OW. The global prevalence of Huntington’s disease: a systematic review and discussion. Neurodegener Dis Manag. 2016;6(4):331–43. doi: 10.2217/nmt-2016-0008
10. Squitieri F, Griguoli A, Capelli G, Porcellini A, D’Alessio B. Epidemiology of Huntington disease: First post-HTT gene analysis of prevalence in Italy. Clin Genet 2016;89(3):367–70. doi: 10.1111/cge.12574
11. Frontali M, Malaspina P, Rossi C, Jacopini AG, Vivona G, Pergola MS, et al. Epidemiological and linkage studies on Huntington’s disease in Italy. Hum Genet. 1990;85(2):165–70. doi: 10.1007/bf00193190
12. Taruscio D, Rocchetti A, Torreri P, Ferrari G, Kodra Y, Salerno P, et al. Il Registro Nazionale Malattie Rare nel contesto nazionale e internazionale - 3° rapporto (dati al 31 Dicembre 2014). Vol. 17, Rapporti ISTISAN. 2017. available from: http://www.hepatitis.iss.it/binary/publ/cont/17_8_web.pdf
13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 2009;6(7): e1000097. doi: 10.1371/journal.pmed.1000097
14. Centro di Coordinamento della Rete Regionale per le Malattie Rare della Lombardia, Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri. Registro Lombardo Malattie Rare (ReLMaR) - Rapporto al 31 Dicembre 2015 Milan; 2016. Available from: http://malattierare.marionegri.it/content/view/152
15. Regione Toscana. Rete Toscana Malattie Rare - Dati Corea di Huntington . 2020 [cited 2020 Jan 27]. Available from: malattierare.toscana.it/dati-statistici/casi/corea-di-huntington/
16. Coordinamento Regionale Malattie Rare. “Malattie Rare in Puglia” - Analisi dei dati al 31/05/2016 Bari; 2016. Available from: https://www.sanita.puglia.it/documents/36106/272175/Malattie+Rare+in+Puglia_Analisi+dei+dati+al+31+maggio+2016/e24d0b0c-cdcb-49a8-873f-331a2631d99b
17. Direzione regionale salute e integrazione sociosanitaria - Area Rete Ospedaliera e Specialistica. MALATTIE RARE NEL LAZIO - Rapporto Anno 2017 Rome; 2019. Available from: http://www.regione.lazio.it/malattierare/allegati/Rapporto_MRL_2017_28marzo2019_def.pdf
18. Comune di Trieste. Piano di Zona 2013-2015 - Ambito 1.2 Trieste [Internet]. 2013. Available from: http://documenti.comune.trieste.it/sociale/PDZ_layout_2013.pdf
19. Stumpo M, Guttmann S, Volpini M, Monaldini M, Manzaroli D, Maffi S, et al. High prevalence of huntington’s disease in San Marino Republic: an epidemiological survey. J Neurol Neurosurg Psychiatry. 2016;87:A60. doi: 10.1136/jnnp-2016-314597.168
20. Mainini P, Lucci B, Guidetti D, Casoli C. Prevalenza della malattia di Huntington nelle provincie di reggio Emilia e Parma. Atti del IIIo Convegno Naz di Neuroepidemiologia. 1982;179–83.
21. Muroni A, Ercoli T, Melas V, Casaglia E, Melis M, Cocco E, et al. Prevalence of Huntington’s Disease in Sardinia, Italy. Mov Disord. 2019;34(S2):A31. https://www.mdsabstracts.org/abstract/prevalence-of-huntingtons-disease-in-sardinia-italy/. Accessed January 29, 2020.
22. Govoni V, Pavoni V, Granieri E, Carreras M, Malagù S, Gandini E, et al. Huntington chorea in the province of Ferrara from 1971 to 1987. Descriptive study. Riv Neurol 1988;58(6):235–40.
23. Pavoni M, Granieri E, Govoni V, Pavoni V, Del Senno L, Mapelli G. Epidemiologic approach to Huntington’s disease in Northern Italy (Ferrara area). Neuroepidemiology 1990;9(6):306–14. doi: 10.1159/000110793
24. Reverberi L, Valzania F, Contardi S, Fioravanti V, Cavallieri F, Codeluppi L. The epidemiology of huntington’s disease in Modena and Reggio Emilia. Neuroepidemiology 2014;43(3–4):171. doi: 10.1159/000369420
25. Groppi C, Barontini F, Bracco L, Sità D, Inzitari D, Amaducci L, et al. Huntington’s chorea: a prevalence study in the Florence area. Acta Neurol Scand 1986;74(4):266–8. doi: 10.1111/j.1600-0404.1986.tb03512.x
26. McColgan P, Tabrizi SJ. Huntington’s disease: a clinical review. Eur J Neurol. 2018;25(1):24–34. doi: 10.1111/ene.13413
27. Malaguti MC, Vanacore N, Ferrari S, Piffer S, Pertile R, Roni R, et al. An unexpected higher prevalence of Parkinson’s disease in females than in males in the province of Trento (Italy): a clues for the etiopathogenesis? Park Relat Disord. 2016;22:e29. doi: 10.1016/j.parkreldis.2015.10.025
28. Riccò M, Garbarino S, Bragazzi NL. Migrant Workers from the Eastern-Mediterranean Region and Occupational Injuries : A Retrospective Database-Based Analysis from North-Eastern Italy. Int J Env Res Public Heal. 2019;16:673. doi: 10.3390/ijerph16040673
29. Taruscio D, Vittozzi L, Rocchetti A, Torreri P, Ferrari L. The occurrence of 275 rare diseases and 47 rare disease groups in Italy. Results from the national registry of rare diseases. Int J Environ Res Public Health. 2018;15(7). 10.3390/ijerph15071470
30. Signorelli C, Riccò M, Odone A. [The role of Health Impact Assessment (HIA) in the decision-making]. | La valutazione di impatto sanitario (VIS) nei processi decisionali. Epidemiol Prev 2011;35 (2):131-5
31. Signorelli C, Riccò M, Odone A. The Italian National health service expenditure on workplace prevention and safety (2006-2013): A national-level analysis. Ann Ig 2016;28(5):313-8 doi: 10.7416/ai.2016.2111
32. Signorelli C, Riccò M. [The Health-Environment Interaction in Italy]. 2011;68(2):374-380
33. Riccò M, Razio B, Panato C, Poletti L, Signorelli C. Knowledge, Attitudes and Practices of Agricultural Workers towards Tetanus Vaccine: a Field Report. Ann Ig 2017;29(4):239–55. doi: 10.7416/ai.2017.2156
34. Manzoli L, Sotgiu G, Magnavita N, Durando P, Barchitta M, Carducci A, et al. Evidence-based approach for continuous improvement of occupational health. Epidemiol Prev 2015;39(4S):81-5
35. Vezzosi L, Riccò M, Agozzino E, Odone A, Signorelli C. Knowledge, attitudes, and practices of general practitioners from the Province of Parma (Northern Italy) towards vaccinations in adults ≥65 year-old. Acta Biomed. 2019;90(9S):71–5. doi: 10.23750/abm.v90i9-S.8704
36. Riccò M, Cattani S, Casagranda F, Gualerzi G, Signorelli C. Knowledge, attitudes, beliefs and practices of occupational physicians towards vaccinations of health care workers: A cross sectional pilot study in North-Eastern Italy. Int J Occup Med Environ Health 2017;30(5):775–90. doi: 10.13075/ijomeh.1896.00895